Pre-made Ublituximab benchmark antibody ( Whole mAb, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ublituximab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ublituximab is an immunomodulator. It binds to CD20.
| Products Name (INN Index) | Pre-Made Ublituximab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody |
|---|---|
| INN Name | Ublituximab |
| Target | MS4A1 |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | LFB Biotechnologies,rEVO Biologics,Johns Hopkins University,TG Therapeutics Inc |
| Conditions Approved | NA |
| Conditions Active | Chronic lymphocytic leukaemia,Multiple sclerosis,Diffuse large B cell lymphoma,Follicular lymphoma,Mantle-cell lymphoma,Non-Hodgkin's lymphoma |
| Conditions Discontinued | Neuromyelitis optica |
| Development Tech | EMABling Platform |
| Previous Name | NA |
| Gm Offical Target Name | MS4A1 |
| Package |
